European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - voriconazole - aspergillosis; candidiasis; mycoses - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.voriconazole accord should be administered primarily to patients with progressive, possibly life-threatening infections.

United States - English - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 200 mg - voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive apergillosis (ia). in clinical trials, the majority of isolates recovered were aspergillus fumigatus . there was a small number of cases of culture-proven disease due to species of aspergillus other than a. fumigatus [see clinical studies (14.1, 14.5) and microbiology (12.4)] . voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see clinical studies (14.2, 14.5) and microbiology (12.4)]. voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (ec) in adults and pediatric patients 2 years of age and older [see clinical studies (14.3, 14.5) and microbiology (12.4

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 50 mg - in clinical trials, the majority of isolates recovered were aspergillus fumigatus . there was a small number of cases of culture-proven disease due to species of aspergillus other than a. fumigatus [see clinical studies (14.1) and clinical pharmacology (12.4)] . [see clinical studies (14.2) and clinical pharmacology (12.4).] [see clinical studies (14.3) and clinical pharmacology (12.4).] [see clinical studies (14.4) and clinical pharmacology (12.4).] specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). therapy may be instituted before the results of the cultures and other laboratory studies are known. however, once these results become available, antifungal therapy should be adjusted ac

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - voriconazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - voriconazole -

United States - English - NLM (National Library of Medicine)

hainan poly pharm. co., ltd. - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections: in clinical trials, the majority of isolates recovered were aspergillus fumigatus . there was a small number of cases of culture-proven disease due to species of aspergillus other than a. fumigatus [ see clinical studies (14.1) and clinical pharmacology (12.4) ]. [ see clinical studies (14.2) and clinical pharmacology (12.4) ] [ see clinical studies (14.3) and clinical pharmacology (12.4) ] [ see clinical studies (14.4) and clinical pharmacology (12.4) ] specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). therapy may be instituted before the results of the cultures and other laboratory studies are known. however, once these results become available, antifungal therapy should be adjusted accordingly. - voriconazole is contraindicated in patients with k

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: nitrogen; sulfobutyl betadex sodium - voriconazole sandoz is indicated for treatment of the following fungal infections: -invasive aspergillosis. -serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). -serious fungal infections caused by scedosporium spp and fusarium spp. -other serious fungal infections, in patients intolerant of, or refractory to, other therapy. -prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Canada - English - Health Canada

teva canada limited - voriconazole - tablet - 50mg - voriconazole 50mg - azoles

Canada - English - Health Canada

teva canada limited - voriconazole - tablet - 200mg - voriconazole 200mg - azoles

Canada - English - Health Canada

auro pharma inc - voriconazole - tablet - 50mg - voriconazole 50mg - azoles